A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults
18 Years - 55 Years
Endpoint Classification: -
Intervention Model: Sequential Assignment
Primary Purpose: Treatment
Verified 01 Sept 2022 by AstraZeneca
No locations available
Participants will receive AZD7442 doses across five fixed-dose cohorts via intravenous (IV) infusions (three cohorts will be administered sequentially, and one cohort will receive co-administration of AZD8895 + AZD1061, mixed into a single infusion) and direct gluteal intramuscular (IM) injections (administered sequentially).
Combination Product: AZD7442
Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
|Placebo Comparator: Placebo|
Placebo will be administered to participants across five fixed-dose cohorts similar to the active treatment.
Participants randomised to placebo will receive the same volume of solution as participants on active treatment.